Chloroxine

Summary

Chloroxine (CHEMBL1200596) is an approved small-molecule antibacterial agent.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 214.04 Da · C9H5Cl2NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200596
Name	Chloroxine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2722
ChEBI	CHEBI:59477
Molecular formula	C9H5Cl2NO
Molecular weight	214.04
InChIKey	WDFKMLRRRCGAKS-UHFFFAOYSA-N

SMILES: C1=CC2=C(C(=C(C=C2Cl)Cl)O)N=C1

IUPAC name: 5,7-dichloroquinolin-8-ol

ChEBI definition: A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 have been substituted by chlorine. A synthetic antibacterial prepared by chlorination of quinolin-8-ol, it is used for the treatment of dandruff and seborrhoeic dermatitis of the scalp.

Pharmacological roles (ChEBI): antibacterial agent, antiseborrheic, antifungal drug.

Also known as: Capitrol, Chloroxine, NSC-3904, SID24715093, SID24715133, SID24813759, SID26749233, CHLOROXINE, SID144205047, SID174006956, SID170465084, Choroxine

Patent coverage: 707 distinct patent families (1,792 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 1,692 (94%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 28 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Lysine-specific demethylase 4E, Streptokinase A, Nuclear receptor ROR-gamma, Survival motor neuron protein, Fructose-bisphosphate aldolase, Prelamin-A/C, Menin/Histone-lysine N-methyltransferase MLL, 5-hydroxytryptamine receptor 1A.

Bioactivity

ChEMBL activities: 24 potent at pChembl ≥ 5 of 42 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P51450	7.1	Potency	79.4	nM	CHEMBL_ACT_5007631
P10520	6.83	EC50	148	nM	CHEMBL_ACT_4893781
P51450	6.55	Potency	281.8	nM	CHEMBL_ACT_4971494
TDP1	6.35	Potency	446.7	nM	CHEMBL_ACT_3931497
ALOX12	6	Potency	1000	nM	CHEMBL_ACT_4529355
HSP90AA1	5.98	AC50	1045	nM	CHEMBL_ACT_7453960
ALOX12	5.72	IC50	1900	nM	CHEMBL_ACT_6305248
MMP14	5.62	Kd	2400	nM	CHEMBL_ACT_25094796
ALOX15	5.62	IC50	2400	nM	CHEMBL_ACT_6305260
HTT	5.55	Potency	2818	nM	CHEMBL_ACT_3749502
A8B2U2	5.5	Potency	3155	nM	CHEMBL_ACT_4598152
TP53	5.5	Potency	3162	nM	CHEMBL_ACT_4846372
ALOX5	5.44	IC50	3600	nM	CHEMBL_ACT_6305259
LMNA	5.4	Potency	3981	nM	CHEMBL_ACT_3643079
P0DTD1	5.34	Kd	4600	nM	CHEMBL_ACT_24819101
OPRK1	5.34	IC50	4560	nM	CHEMBL_ACT_5564043
C7C422	5.31	IC50	4900	nM	CHEMBL_ACT_25632618
SLC6A2	5.29	AC50	5192	nM	CHEMBL_ACT_25145808
LMNA	5.2	Potency	6310	nM	CHEMBL_ACT_3665414
TDP1	5.15	Potency	7080	nM	CHEMBL_ACT_3931525
ALDH1A1	5.15	Potency	7080	nM	CHEMBL_ACT_4172789
P0DTD1	5.14	IC50	7240	nM	CHEMBL_ACT_24819099
TP53	5.1	Potency	7943	nM	CHEMBL_ACT_4854820
HTT	5.05	Potency	8912	nM	CHEMBL_ACT_3751420

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).